AGC to Exhibit Next-generation Mobility-enabling Products & Technologies at CES2023
AGC, the provider of a wide range of solutions from automotive and display glass to the cutting-edge materials essential for next-generation mobility, will exhibit at CES2023, the world's leading technology trade show, being held in Las Vegas during January 3-8, 2023. The 3rd and 4th will be reserved for media and pre-show keynotes; the fair will be open to the public from the 5th. The company will exhibit 17 of its products, including several brand new releases.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221204005064/en/
AGC‘s booth at CES2023 (#4377, Vehicle Tech & Advanced Mobility, LVCC - West Hall) (Graphic: Business Wire)
AGC has been a leading manufacturer of architectural, automotive and display glass for more than 110 years, supplying high-quality products worldwide. Today, the company leverages its technological expertise in the fields of glass, electronics, chemicals, and ceramics to provide a variety of cutting-edge materials and services that meet the growing demand for autonomous driving and other mobility services.
One of the highlights of AGC’s exhibits at CES will be the company’s FIR (far infrared) camera-compatible windshield, featuring special glass that allows far-infrared rays to penetrate, something which ordinary automotive glass does not. This allows sensor fusion of regular visible and FIR cameras mounted behind the windshield and reduces the risk of accidents involving pedestrians and cyclists at night or in bad weather.
Another highlight of the exhibit will be AGC’s glass composition and processing technologies; these provide the strength and optical capabilities needed to mount and deploy the cameras and the LiDAR (light detection and ranging) components required for autonomous driving. A wide range of other solutions will also be exhibited, including the 5G-sub6 Glass Antenna and the 3D Curved Cover Glass For Automotive Interior Displays. For a complete list, please refer to the Appendix.
Yoshinori Hirai, President & CEO of AGC, commented, “CES is one of the world's most influential technology trade shows, and we see it as the best stage on which to showcase AGC's capabilities to the world. We strongly believe our next-generation mobility-related products and solutions will create a buzz among CES visitors. The materials we offer have an appeal that can only be successfully conveyed when they are seen and experienced up close. We hope that as many people as possible will learn firsthand about the value we offer and make good use of our products.”
Please stop by our booth and see the various ways in which AGC is pushing the boundaries of technology. If you would like to interview an AGC spokesperson, please contact us.
Booth information
LVCC - West Hall
Vehicle Tech & Advanced Mobility
#4377
In the same West Hall there will be a separate booth (#6557) dedicated to our "Wideye" solutions and another for our "FeelinGlass" product (#6674).
About CES
Owned and produced by the Consumer Technology Association (CTA)®, CES® is the world’s most influential tech event; the proving ground for breakthrough technologies and global innovators where the world's biggest brands do business and meet new partners, and the sharpest innovators hit the stage. CES 2023 will showcase the latest technological innovations dedicated to addressing the world’s most pressing global challenges in support of the United Nations’ efforts to advance human security for all. Please visit https://www.ces.tech/ for further details.
About AGC Inc.
AGC Inc. (Headquarters: Tokyo, President & CEO: Yoshinori Hirai) is the parent company of the AGC Group, a world-leading glass solution provider and supplier of flat, automotive and display glass, chemicals, ceramics and other high-tech materials and components. Building on more than a century of technical innovation, the AGC Group has developed a wide range of cutting-edge products. The Group employs some 56,000 people worldwide and generates annual sales of around 1.7 trillion Japanese yen (approx. US$ 12.3bn) through its operations in more than 30 countries and regions. For more information, please visit https://www.agc.com/en/index.html
Appendix (List of exhibited products and technologies)
Product Name |
Brand name |
Usage/Application |
Appearing for the first time? |
Features |
FIR (far infrared) camera-compatible windshield |
|
Automotive windshields |
Yes |
|
5 G-sub 6 Glass Antenna |
|
Automotive Glazing |
Yes |
|
3D Curved Cover Glass
|
|
Automotive Interior Display
|
No |
Anti-reflection / Anti-fingerprint coating |
Porous Aminosilica |
|
CO2 Direct Air Capture (DAC) / Acid gas removal /
|
Yes |
|
Thermal Conductive-Electrical Insulation Film |
|
Thermal interface material for power semiconductors |
Yes |
|
Super-Hydrophobic Glass |
|
Window and roof glass for mobility applications;
|
Yes |
|
Windshield damage detection smart sensor |
Jack by AGC |
Self-powered device that detects, diagnoses and notifies in real-time glass damage to windshields |
Prototype has been previously presented |
|
Glass B-Pillar With Invisible Sensor Integration |
Wideye by AGC |
Lateral integration of a LiDAR sensor in a B-Pillar made of infrared transparent glass |
Prototype has been previously presented |
|
Cover Glass |
EG-A1, EG-A2 |
LiDAR, Camera |
Yes |
|
Aspherical Glass Lenses |
Aspherical Glass Molded Lenses |
LiDAR, Camera, Projector, Optical communication, AR/VR/MR, Lighting |
No |
|
Optical Filter |
IR Pass Filter, Band Pass Filter, Mirror |
Cover/noise removal for LiDAR, Camera, UV disinfection, semiconductor manufacturing |
No |
|
Glass Ceramics Substrate |
GCHPTM |
LEDs, semiconductors, lasers |
No |
|
DOE and Diffuser |
DOE and diffuser |
ToF sensor, LiDAR, cameras, projectors, optical communication, AR/VR/MR, lighting |
No |
|
Anti-glare glass |
New AG (anti-glare) glass for high-definition panels |
High-definition notebook PCs, tablets and monitors |
Yes |
|
Chemically engineered high strength glass |
Dragontrail |
Cover glass for displays of smartphones, tablets, PCs, etc. (electronic devices requiring cover glass) |
No |
|
FWA antenna |
"5G Millimeter Wave Transparent Antenna for FWA " |
Antenna is thin and transparent,
|
No |
|
Transparent Reflector Fence |
|
Local 5G networks |
Yes (overseas) |
|
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221204005064/en/
Contact information
Overseas media inquiries
Media Inquiries
Public Relations, AGC Inc.
Marunouchi 1-5-1, Chiyoda-ku, Tokyo 100-8405 JAPAN
Tel: +81 (0)3-3218-5603
Weber Shandwick Japan
Reina Matsushita; tel: +81 (0)80 2375 0295
Masashi Nonaka; tel: +81 (0)80 1037 7879
E-mail rmatsushita@webershandwick.com / mnonaka@webershandwick.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom